Company / SG&A Expense
Voyager Therapeutics, Inc. SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$35.8M
FY2025
5-year range
$31.0M / $37.2M
FY2021-FY2025
Trend
+15.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
SG&A Expense has fluctuated over the past 10 years, ranging from $5M in FY2016 to $37M in FY2023.
Based on SEC 10-K filings.
$36M in FY2025 with a 5-year CAGR of +1.2%.
Improved from $37M to $36M over the past 2 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +0.8%
- 5-Year CAGR
- +1.2%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +1.2%, indicating consistent growth.
- In FY2025, sg&a expense increased 15.6% year-over-year.
- Peak sg&a expense was recorded in FY2023.
- Lowest sg&a expense in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score 0.34 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $35.8M | +15.6% |
| FY2024 | $31.0M | -16.8% |
| FY2023 | $37.2M | +6.4% |
| FY2022 | $35.0M | -3.7% |
| FY2021 | $36.3M | +7.5% |
| FY2020 | $33.8M | +71.3% |
| FY2019 | $19.7M | +48.7% |
| FY2018 | $13.3M | +33.9% |
| FY2017 | $9.9M | +81.2% |
| FY2016 | $5.5M | +277.2% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026